Family Health Service Authority

This part details how payments will be calculated to those pharmacies who have had their contract with their local Primary Care Trust in England or Local Health Board in Wales suspended or who are suspended by direction of the FHSAA (Family Health Services Appeal Authority). Suspension of a contract would be imposed, for example, to protect patients if there is evidence of substandard clinical practice or personal behaviour. 

Sponsoring Agency. The Children s and Communities Mental Health Services Improvement Act of 1992 authorized the Comprehensive Community Mental Health Services for Children and Their Families Program (ccmhp), which is administered by the Center for Mental Health Services/Substance Abuse and Mental Health Services Administration (samhsa). samhsa is mandated to improve the quality and availability of prevention, treatment, and rehabilitative services for mental illness and substance abuse in order to reduce illness, death, disability, and other societal cost caused by these problems (Substance Abuse and Mental Health Services Administration, 2002). The Center for Mental Health Services (CMHs), placed within samhsa, aims to improve the availability and accessibility of high-quality care for people affected by or at risk for mental disorders and works toward the development of an effective community-based mental health infrastructure for the nation (Substance Abuse and Mental Health Services Administration, 2002). 

Patient data collection is an extremely critical component of a value-added service. The information collected provides pharmacists with important baseline and monitoring parameters for patients. The amount and type of information needed from the patient or other health care providers may differ depending on the service, but nonetheless, this information is the foundation on which the other components of the service are built. Forms can be developed to help pharmacists collect this information (see Figs. 25-2 through 25-4). In addition, some consideration should be given to how this information will be stored (e.g., paper charts or electronic patient database). The information that should be collected from the patient includes demographic information, medical history, family history, and medication history. Since some of the information may need to be collected from other providers and health care institutions, an authorization to release medical information should be signed by the patient and kept as part of the chart (see Fig. 25-5). Lastly, pharmacists should ensure that their site is in compliance with the Health Insurance Portability and Accountability Act (HIPPA) and reinforce to their patients that the information they provide is confidential and secure at the pharmacy. 

The author (M.K.) is most grateful to Dr. A. Brossi, Department of Health and Human Services, National Institutes of Health, who carefully read and made critical comments on various portions of the manuscript. Thanks are also due Professor Dr. Toshio Honda, Institute of Medicinal Chemistry, Hoshi University, Tokyo, for critical reading of the text. The author is extremely grateful for family support and especially acknowledges Miss Namie Koizumi for preparing all the drawings and typing the manuscript. 

---